On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- LDP Economic Growth HQ Hammers Out Proposal for Honebuto Paper
May 26, 2021
- Moderna Vaccine Likely to Be Used for Workplace Vaccination
May 26, 2021
- Japan Eyes Pfizer Vaccine Use in Younger People, Longer Refrigerator Storage
May 26, 2021
- 2nd Humira Biosimilar, 1st NovoRapid Follow-On Gets Japan Listing on May 26
May 25, 2021
- MHLW Panel Backs Japan’s 1st Oncolytic Virus for Conditional Approval
May 25, 2021
- MHLW Grants Orphan Status to Eculizumab, 2 More APIs
May 25, 2021
- Japan Hails Janssen Vaccine Submission as New Option: Spokesman
May 25, 2021
- MOF Panel’s Proposal Urges More Stringent Drug Cost Control, Revisiting of Semi-Automatic Listing
May 24, 2021
- Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
- LDP Project Team Submits Proposal to Boost Drug Discovery Capabilities
May 24, 2021
- PMDA Review Report: Flexible Discussions Needed for Eligibility of AstraZeneca Vaccine
May 24, 2021
- PMDA Reviewing New Safety Risk for Keytruda
May 24, 2021
- Japan Approves Moderna and AstraZeneca COVID-19 Vaccines
May 21, 2021
- AstraZeneca, Moderna COVID-19 Vaccines in Line for Japan Approval on May 21
May 21, 2021
- Give AstraZeneca Shots to People Who Want, Regardless of Priority Order: Lawmakers
May 21, 2021
- Japan Govt Eyes Expedited Approval Process to Push Homegrown Vaccines
May 20, 2021
- LDP Panels Submit Proposal to PM for Commercialization of Japan-Made Vaccines
May 19, 2021
- LDP Study Group’s Draft Proposal Urges Price Maintenance for Patented Drugs
May 19, 2021
- Pharma to Govt: Maintain Prices of Patented Drugs, It’s the Global Standard
May 18, 2021
- MHLW Proposes Lifting Domestic Ban on Cannabis-Derived Drugs, Seeking “Ingredient-Based” Regulation
May 18, 2021
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…